Lista de obras - Khandan Keyomarsi - Dominio Público Uruguay

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

artículo científico publicado en 2014

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

artículo científico publicado en 2015

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

artículo científico publicado en 2016

Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.

artículo científico publicado en 2003

Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.

artículo científico publicado en 2009

An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.

artículo científico publicado en 1990

Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

artículo científico publicado en 2005

Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.

artículo científico publicado en 2008

Biomarkers in Neoadjuvant Trials

artículo científico publicado en 2009

Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles ⬇️

artículo científico publicado el 30 de noviembre de 2011

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.

artículo científico publicado en 2017

CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.

artículo científico publicado en 2017

Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E

artículo científico publicado en 2011

Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.

artículo científico publicado en 2016

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

artículo científico publicado en 2004

Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.

artículo científico publicado en 2010

Cyclin E deregulation is an early event in the development of breast cancer.

artículo científico publicado en 2008

Cyclin E is a more powerful predictor of breast cancer outcome than proliferation

artículo científico publicado en 2003

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.

artículo científico publicado en 2017

Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy.

artículo científico publicado en 2007

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

artículo científico publicado en 2017

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

artículo científico publicado en 2016

Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer

artículo científico publicado en 2016

DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer

artículo científico publicado en 2009

Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer

artículo científico publicado en 2006

Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta.

artículo científico publicado en 2007

Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

artículo científico publicado en 2014

Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer

artículo científico publicado en 2013

Erratum to "Expression of an estrogen receptor alpha variant protein in cell lines and tumors"

artículo científico publicado en 2000

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

artículo científico publicado en 2015

Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion

scientific article published on 06 April 2016

Expression of an estrogen receptor alpha variant protein in cell lines and tumors

scientific article published on 01 April 2000

Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.

artículo científico publicado en 2006

Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.

scientific article published on 16 August 2013

How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

artículo científico publicado en 2015

Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells

artículo científico publicado en 2014

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

artículo científico publicado en 2017

LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients ⬇️

artículo científico publicado el 29 de marzo de 2012

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

artículo científico publicado en 1999

Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer ⬇️

artículo científico publicado el 1 de abril de 2012

Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification

artículo científico publicado en 2010

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome

artículo científico publicado en 2004

MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells.

artículo científico publicado en 2011

Modification of cell proliferation with inhibitors

artículo científico publicado el 1 de abril de 1992

Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.

artículo científico publicado en 2007

PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness

artículo científico publicado en 2016

PKCiota promotes ovarian tumor progression through deregulation of cyclin E.

artículo científico publicado en 2015

Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase

artículo científico publicado en 2001

Role of cell cycle in mediating sensitivity to radiotherapy

artículo científico publicado en 2004

Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells

artículo científico publicado en 2010

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer

artículo científico publicado en 2016

Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner

artículo científico publicado en 2013

Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.

artículo científico publicado en 1994

Targeting low molecular weight cyclin E (LMW-E) in breast cancer.

artículo científico publicado en 2011

The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway.

artículo científico publicado en 1999

The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.

artículo científico publicado en 2010

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

artículo científico publicado en 1993

The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase

artículo científico publicado en 2014

Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms

artículo científico publicado en 2001

[47] Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with 14C and 3H

artículo científico publicado en 1986

Lista de obras de Khandan Keyomarsi

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells.

Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.

An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.

Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.

Biomarkers in Neoadjuvant Trials

Breaking the cycle: An insight into the role of ERα in eukaryotic cell cycles ⬇️

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.

CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.

Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E

Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.

Cyclin E deregulation is an early event in the development of breast cancer.

Cyclin E is a more powerful predictor of breast cancer outcome than proliferation

Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.

Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy.

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer

DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer

Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer

Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta.

Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer

Erratum to "Expression of an estrogen receptor alpha variant protein in cell lines and tumors"

Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.

Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion

Expression of an estrogen receptor alpha variant protein in cell lines and tumors

Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.

Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.

How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients ⬇️

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer ⬇️

Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome

MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells.

Modification of cell proliferation with inhibitors

Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.

PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness

PKCiota promotes ovarian tumor progression through deregulation of cyclin E.

Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase

Role of cell cycle in mediating sensitivity to radiotherapy

Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer

Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner

Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.

Targeting low molecular weight cyclin E (LMW-E) in breast cancer.

The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway.

The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase

Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms

[47] Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with 14C and 3H